[Form 4] CG Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Leonard E. Post, a director of CG Oncology, Inc. (CGON), reported transactions dated 09/15/2025. He exercised a director stock option with a $0.60 exercise price to acquire 1,000 shares (option fully vested). On the same date he sold 1,000 shares at $35.10 per share; the filing states the sale was effected under a Rule 10b5-1 trading plan adopted by the reporting person on 09/06/2024. Following these transactions, the filing reports total beneficial ownership of 124,077 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Post on 09/16/2025.

Positive

• Sale executed under a Rule 10b5-1 trading plan, indicating pre-planned and compliant insider selling
• Director exercised fully vested options (exercise price $0.60) to acquire 1,000 shares

Negative

• Director sold 1,000 shares (reported sale at $35.10), which reduces the director's immediate liquid stake
• No additional context on the proportionate size of the transactions relative to holdings or incentives is provided in the filing

Insights

Financial Analyst

TL;DR: Director exercised vested options and sold an equal number of shares under a Rule 10b5-1 plan; net ownership unchanged by these paired transactions.

The reported activity shows a typical option exercise and contemporaneous sale of the same number of shares. The exercise price of $0.60 and reported sale price of $35.10 imply a realized gain on the disposed shares relative to exercise cost for those specific shares, while overall beneficial ownership remains large at 124,077 shares. The use of a Rule 10b5-1 plan indicates the sale was pre-planned, which reduces concerns about opportunistic trading tied to undisclosed company developments. Transaction sizes are explicitly stated in the filing; no additional financial metrics or company-level impacts are provided.

Corporate Governance Expert

TL;DR: Governance practices appear compliant: disclosure filed on Form 4 and sale executed under a documented 10b5-1 plan.

The Form 4 discloses the reporting person's status as a director and provides clear transaction codes and explanations. The filing notes the Rule 10b5-1 trading plan adoption date (09/06/2024) and indicates the stock option was fully vested. These elements support transparency and adherence to insider trading compliance processes. The signature by an attorney-in-fact is correctly provided. The filing contains no disclosure of any other governance issues or related-party arrangements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

POST LEONARD E

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

400 SPECTRUM CENTER DRIVE, SUITE 2040

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2025		M		1,000	A	$0.6	1,000	D
Common Stock	09/15/2025		S(1)		1,000	D	$35.1	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$0.6	09/15/2025		M			1,000	(2)	07/08/2028	Common Stock	1,000	$0	124,077	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024.

2. Fully vested

	/s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Leonard E. Post report for CGON?

The Form 4 reports that on 09/15/2025 Mr. Post exercised a director stock option for 1,000 shares at $0.60 and sold 1,000 shares at $35.10.

Were the sales by the CGON director part of a trading plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 09/06/2024.

How many shares does Leonard E. Post beneficially own after the reported transactions?

The Form 4 reports 124,077 shares beneficially owned following the reported transactions.

Is the exercised option vested?

Yes. The filing notes the director stock option that was exercised was fully vested.

Who signed the Form 4 filing?

The Form 4 is signed by Joshua F. Patterson, Attorney-in-Fact for Leonard Post on 09/16/2025.